These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 38462751

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. QT prolongation in the STREAM Stage 1 Trial.
    Hughes G, Bern H, Chiang CY, Goodall RL, Nunn AJ, Rusen ID, Meredith SK.
    Int J Tuberc Lung Dis; 2022 Apr 01; 26(4):334-340. PubMed ID: 35351238
    [Abstract] [Full Text] [Related]

  • 3. How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial.
    Motta I, Cusinato M, Ludman AJ, Lachenal N, Dodd M, Soe M, Abdrasuliev T, Usmanova R, Butabekov I, Nikolaevna TZ, Liverko I, Parpieva N, Moodliar R, Solodovnikova V, Kazounis E, Nyang'wa B-T, Fielding KL, Berry C.
    Antimicrob Agents Chemother; 2024 Jul 09; 68(7):e0053624. PubMed ID: 38842323
    [Abstract] [Full Text] [Related]

  • 4. ECG monitoring in STREAM Stage 1: can we identify those at increased risk of QT prolongation?
    Hughes G, Bern H, Chiang CY, Goodall RL, Nunn AJ, Rusen ID, Meredith SK.
    Int J Tuberc Lung Dis; 2022 Nov 01; 26(11):1065-1070. PubMed ID: 36281045
    [Abstract] [Full Text] [Related]

  • 5. Clofazimine and QT prolongation in the treatment of rifampicin-resistant tuberculosis: Findings of aDSM in Taiwan.
    Lin CJ, Chen JH, Chien ST, Huang YW, Lin CB, Lee JJ, Lee CH, Yu MC, Chiang CY.
    J Microbiol Immunol Infect; 2024 Oct 01; 57(5):791-800. PubMed ID: 39160114
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis.
    Abdelwahab MT, Court R, Everitt D, Diacon AH, Dawson R, Svensson EM, Maartens G, Denti P.
    Antimicrob Agents Chemother; 2021 Jun 17; 65(7):e0268720. PubMed ID: 33875426
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Correlation of Moxifloxacin Concentration, C-Reactive Protein, and Inflammatory Cytokines on QTc Interval in Rifampicin-Resistant Tuberculosis Patients Treated with Shorter Regimens.
    Kusmiati T, Mertaniasih NM, Putranto JNE, Suprapti B, Luthfah N, Soedarsono S, Koesoemoprodjo W, Sari AP.
    Acta Med Indones; 2022 Jan 17; 54(1):19-27. PubMed ID: 35398822
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
    Dooley KE, Rosenkranz SL, Conradie F, Moran L, Hafner R, von Groote-Bidlingmaier F, Lama JR, Shenje J, De Los Rios J, Comins K, Morganroth J, Diacon AH, Cramer YS, Donahue K, Maartens G, AIDS Clinical Trials Group (ACTG) A5343 DELIBERATE Study Team.
    Lancet Infect Dis; 2021 Jul 17; 21(7):975-983. PubMed ID: 33587897
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.